Urticaria Reported in Trial of Investigational HIV mRNA Vaccines
By Elana Gotkine HealthDay Reporter
MONDAY, May 5, 2025 -- Urticaria is seen in association with experimental HIV-1 mRNA vaccination, according to a study published online April 29 in the Annals of Internal Medicine.
Sharon A. Riddler, M.D., from the University of Pittsburgh, and colleagues examined the safety and tolerability of three investigational HIV-1 trimer mRNA vaccines in a phase 1, randomized trial. A total of 108 volunteers aged 18 to 55 years without HIV-1 were randomly assigned to six vaccine groups (gp140 soluble trimer, gp151 membrane-bound trimer, and gp151 CD4KO membrane-bound trimer at doses of 100 and 250 mcg).
The researchers found that mild-to-moderate local and systemic solicited events occurred frequently. A total of 190 unsolicited adverse events were reported by 80 participants; 30 were considered to be related to a study product. Overall, 73 percent of the related adverse events were mild; the rest were moderate. Of the related adverse events, urticaria was reported by seven participants (7 percent); at 12 months, four of these participants had unresolved, intermittent urticaria. No associations were seen for demographic characteristics, history of allergy or medication use, or COVID-19 with urticaria in a post-hoc analysis. Among participants with versus without urticaria, 100 versus 37 percent reported previous Moderna COVID-19 vaccination; 29 versus 76 percent reported previous Pfizer-BioNTech COVID-19 vaccination; and 0 versus 5 percent reported no previous mRNA COVID-19 vaccination.
"The HVTN 302 study vaccines were generally safe and tolerable, with frequent but typically mild-to-moderate local and systemic reactogenicity events, as seen previously with licensed mRNA COVID-19 vaccines," the authors write.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2025
Read this next
Initiation of HIV PrEP in Young Adults Rose in Recent Years
TUESDAY, June 3, 2025 -- Dispensing and initiation of HIV preexposure prophylaxis (PrEP) among young adults increased from 2016 through 2023, according to a study published online...
Parents Appear Receptive to Children Receiving HPV Vaccine at 9 or 10 Years of Age
MONDAY, June 2, 2025 -- Clinicians consider administration of human papillomavirus (HPV) vaccine as feasible at age 9 to 10 years, and parents appear to be receptive to discussing...
ACP Issues Clinical Guideline for Statin Use in Persons With HIV
THURSDAY, May 29, 2025 -- In a clinical guideline issued by the American College of Physicians and published online May 27 in the Annals of Internal Medicine, recommendations are...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.